MONISTAT 7 CREAM COMBINATION PACK OTC
Generic Name and Formulations:
Miconazole nitrate 2% (vaginal crm), miconazole nitrate 2% (topical crm).
Prestige Brands, Inc.
Indications for MONISTAT 7 CREAM COMBINATION PACK:
1 supp or 1 applicatorful vaginally daily at bedtime for 7 nights. External crm: apply twice daily as needed.
Concomitant use of contraceptive diaphragm, condoms, or tampons: not recommended. Confirm diagnosis by KOH smears and/or cultures. If ineffective, reconfirm diagnosis before repeating therapy. Discontinue if irritation develops. 1st trimester of pregnancy. Nursing mothers.
May potentiate warfarin.
Vulvovaginal burning, itching or irritation, cramps, headache, rash, urticaria.
Combination Pack—7x100mg supp (w. applicator) + 9g topical crm
Crm Combination Pack—7 prefilled applicators + 9g topical crm
Crm—45g (w. applicators)
Crm—7 disposable applicators
Supp—7 (w. applicator)
Clinical Pain Advisor Articles
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Tools to Address the Opioid Crisis
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- Half of the Responders to Our Poll Agree With the Approval of Dsuvia: We Want to Hear From You
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- FDA Panel Votes in Favor of Abuse-Deterrent Oxycodone Reformulation
- FDA Proposes New Restrictions on Sale of Electronic Nicotine Delivery Systems
- Central Sensitization in Greater Trochanteric Pain Syndrome
- Pain Acceptance May Reduce Headache-Related Disability in Migraine
- FDA Issues Safety Alert Regarding Intrathecal Delivery of Pain Meds